What happened with HAE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Haemonetics’ largest business serves hospitals, helping clinicians assess blood clotting, manage blood use and close catheter access sites after procedures. Hospitals buy products such as TEG 6s clotting analyzers and VASCADE closure devices, along with related disposable supplies and software. Hospital and plasma-collection sales together provide most of the company’s revenue.
Its Plasma business supplies centers that collect plasma for pharmaceutical manufacturing. Customers buy NexSys PCS collection devices, the disposables used with them and NexLynk DMS software to manage donors and collection workflows. This business depends chiefly on demand for plasma-derived therapies, particularly immunoglobulin. A smaller Blood Center business sells equipment and supplies for collecting blood components to organizations such as the American Red Cross.
Plasma sales rely heavily on a few large customers, with one customer contributing a substantial share of company-wide revenue. Medical-device regulation also limits which products and uses Haemonetics can market: new devices and new uses generally need FDA authorization in the United States, and authorized indications may be restricted.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Haemonetics also depends on demand for plasma-derived therapies and plasma collection volumes; Fresenius and Terumo BCT are important plasma-device rivals missing from this list.
Abbott competes with Haemonetics for purchases of devices that close vascular entry sites after procedures and devices that assess coronary blood flow. Watch Abbott's advances in closure-device complications and workflow, where Haemonetics competes with VASCADE and PerQseal, and in coronary assessment, where it sells OptoWire.
Teleflex competes for hospitals' and healthcare providers' purchases of devices that close vascular entry sites, directly challenging Haemonetics' VASCADE and PerQseal. Its closure products' clinical benefits, ease of use and cost-effectiveness are the developments to watch for pressure on those devices.
LivaNova competes with Haemonetics' Cell Saver by selling systems that recover a patient's blood during surgery for reinfusion. Watch its autotransfusion products' reliability, ease of use, service and price: Haemonetics says high-volume systems use similar technology, making those differences important.
Cerus and Haemonetics share exposure to blood centers' platelet and plasma collection volumes for transfusion: Haemonetics sells collection systems, while Cerus sells INTERCEPT systems that reduce pathogens in the donated components. Cerus's platelet and plasma product sales offer a view of this transfusion market, not the plasma collected for pharmaceutical manufacturing.
Boston Scientific competes with Haemonetics for interventional cardiologists' purchases of devices that assess coronary blood flow. Its coronary-physiology product developments are relevant to OptoWire, Haemonetics' pressure-measuring guidewire used to support coronary artery disease diagnosis and treatment.
Philips competes with Haemonetics in devices that help clinicians assess coronary blood flow, including the market served by OptoWire. Watch Philips's coronary-physiology offerings rather than its broader Diagnosis & Treatment revenue, which also includes imaging, software and services.
Boston Scientific Corp. earningsBSX
Boston Scientific’s report will show whether its coronary-physiology products are winning purchases that might otherwise go to Haemonetics’ OptoWire.
Watch Boston Scientific’s coronary-physiology developments, not its overall results as a proxy for OptoWire. Stronger product progress and adoption would mean interventional cardiologists are more likely to choose Boston Scientific’s approach, increasing competition for OptoWire. Limited progress would offer less evidence of pressure, but would not establish that OptoWire sales are growing.
Fed Interest Rate Decision
The Fed’s rate decision signals the direction of borrowing costs across the economy; higher rates can raise Haemonetics’ interest expense on debt that reprices and leave less earnings after interest, while lower rates can ease that cost.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed signals higher economy-wide borrowing costs, interest on Haemonetics’ debt that reprices may rise, leaving less of its business earnings after interest; fixed-rate borrowing is not directly repriced by the decision.
If it comes in below expectations
If the Fed signals lower economy-wide borrowing costs, interest on Haemonetics’ debt that reprices may fall, leaving more of its business earnings after interest; fixed-rate borrowing is not directly repriced by the decision.
Teleflex Incorporated earningsTFX
Teleflex’s report will show whether hospitals are still buying vascular-closure devices that compete with Haemonetics’ VASCADE and PerQseal.
Look for what Teleflex says about its closure products’ clinical benefits, ease of use and cost-effectiveness, alongside sales. Evidence of stronger adoption would mean hospitals are buying those advantages, intensifying competition for Haemonetics’ VASCADE and PerQseal. Weak adoption or sales would suggest less pressure, but would not prove demand for Haemonetics’ own devices has improved.
LivaNova PLC earningsLIVN
LivaNova’s report will show how hospitals are responding to its systems for recovering and reinfusing a patient’s blood during surgery, which compete with Haemonetics’ Cell Saver.
Look at LivaNova’s autotransfusion product performance and what it says about reliability, ease of use, service and price. If those factors are drawing demand, hospitals may direct purchases to LivaNova, putting more pressure on Cell Saver. Weaker traction would suggest less pressure from this competitor, but would not settle demand for Cell Saver.
Haemonetics Corporation earningsThis company
Haemonetics’ report will show whether Hospital revenue can keep growing enough to offset the decline in Blood Center, and whether that growth supports its gross margin.
Read Hospital and Blood Center revenue alongside gross margin. Hospital growth, a narrowing Blood Center decline and a stable margin would show that Hospital is replacing lost revenue without eroding the overall margin on products. Slower Hospital growth, continued Blood Center declines or a falling margin would show that offset is less secure. The test is whether Hospital can keep supporting revenue and gross margin.
Cerus Corp earningsCERS
Cerus’s platelet and plasma product sales will offer a read on blood centers’ transfusion-component activity, where Haemonetics sells collection equipment.
Watch whether Cerus’s platelet and plasma product sales strengthen or weaken. Stronger sales would suggest more blood-center activity in transfusion components, a more supportive setting for demand for Haemonetics’ collection equipment; weaker sales would suggest less activity and less support. Cerus’s products treat components for transfusion, not plasma collected for pharmaceutical manufacturing, so its results are not a direct measure of Haemonetics’ Plasma business.
